Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.37 |
| ▸ | GABRE | P78334 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3517296 | 1.00 | PLG (0.42) | PLGPLATLMNAANPEPENPEP | |
| SCHEMBL17935800 | 1.00 | PLG (0.42) | PLGPLATLMNAANPEPENPEP | |
| SCHEMBL20178640 | 1.00 | PLG (0.42) | PLGPLATLMNAANPEPENPEP | |
| SCHEMBL7878856 | 0.88 | KDM4E (0.38) | PLGPLATLMNAANPEPENPEP | |
| SCHEMBL16943496 | 0.82 | LMNA (0.41) | PLGPLATLMNAANPEPENPEP | |
| SCHEMBL16943490 | 0.82 | LMNA (0.41) | PLGPLATLMNAANPEPENPEP | |
| SCHEMBL16943500 | 0.82 | LMNA (0.41) | PLGPLATLMNAANPEPENPEP | |
| SCHEMBL4429096 | 0.82 | SMN1; SMN2 (0.46) | HCAR2SHBGKMT2ANPSR1 | |
| SCHEMBL1805066 | 0.81 | LMNA (0.43) | PLGPLATLMNAANPEPENPEP | |
| SCHEMBL13713727 | 0.81 | LMNA (0.43) | PLGPLATLMNAANPEPENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185007-B1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2018-05-23 | — | — | EP | claimed |
| US-20160205978-A1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2016-07-21 | — | — | US | claimed |
| US-20100311786-A1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2010-12-09 | — | — | US | claimed |
| US-10172378-B2 | Mono- or bicyclic carboxylic acids as off-note blockers | GIVAUDAN, SA (CH) | 2019-01-08 | — | — | US | disclosed |
| EP-2185007-B1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2018-05-23 | — | — | EP | disclosed |
| US-20160205978-A1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2016-07-21 | — | — | US | disclosed |
| US-20160205978-A1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2016-07-21 | — | — | US | disclosed |
| WO-2013072332-A1 | METHODS OF USING ANTAGONISTS OF BITTER TASTE RECEPTORS | GIVAUDAN SA (CH) | 2013-05-23 | — | — | WO | disclosed |
| US-20100311786-A1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311786-A1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2010-12-09 | — | — | US | disclosed |
| EP-2185007-A2 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | Givaudan SA (CH) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009015504-A2 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311786-A1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | SORD, GLUL, ASNS | PLG 4283/4885PLAT 4479/4885LMNA 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.